Literature DB >> 19912575

Higher HLA class I expression in renal cell carcinoma than in autologous normal tissue.

P Sáenz-López1, C Gouttefangeas, J Hennenlotter, A Concha, I Maleno, F Ruiz-Cabello, J M Cózar, M Tallada, A Stenzl, H-G Rammensee, F Garrido, T Cabrera.   

Abstract

A total of 93 frozen primary renal cell carcinoma (RCC) samples and 31 frozen samples of corresponding normal renal tissue were analyzed for human leukocyte antigen (HLA) class I and HLA-DR expression. Unexpectedly, HLA class I expression was much higher on RCC cells than on normal renal tubular cells. Immunohistochemistry analysis of frozen and paraffin-embedded tissue samples, applying an extended panel of specific anti-HLA monoclonal antibodies, showed elevated HLA class I antigen expression in 95.6% of the tumors vs only 12.9% of normal renal tissues. These findings were confirmed by molecular analysis of HLA heavy chain and beta2-microglobulin (beta2m) transcription levels using quantitative real-time polymerase chain reaction (PCR) on microdissected tissue samples (isolated tumor nests and autologous normal renal tubules) from four patients. These results might help to explain the relatively high success rate of immunotherapy in patients with RCC. The molecular mechanism underlying the increased HLA class I expression in RCC has yet to be elucidated.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19912575     DOI: 10.1111/j.1399-0039.2009.01409.x

Source DB:  PubMed          Journal:  Tissue Antigens        ISSN: 0001-2815


  7 in total

1.  Quantification of HLA class I molecules on renal cell carcinoma using Edman degradation.

Authors:  Juliane S Stickel; Natalie Stickel; Jörg Hennenlotter; Karin Klingel; Arnulf Stenzl; Hans-Georg Rammensee; Stefan Stevanović
Journal:  BMC Urol       Date:  2011-01-20       Impact factor: 2.264

2.  Comparative expression profiling for human endoplasmic reticulum-resident aminopeptidases 1 and 2 in normal kidney versus distinct renal cell carcinoma subtypes.

Authors:  Christine G Stoehr; Maike Buettner-Herold; Esther Kamphausen; Simone Bertz; Arndt Hartmann; Barbara Seliger
Journal:  Int J Clin Exp Pathol       Date:  2013-05-15

3.  Pan-cancer association of HLA gene expression with cancer prognosis and immunotherapy efficacy.

Authors:  Evelien Schaafsma; Chloe M Fugle; Xiaofeng Wang; Chao Cheng
Journal:  Br J Cancer       Date:  2021-05-12       Impact factor: 9.075

Review 4.  Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation.

Authors:  Karthik Dhatchinamoorthy; Jeff D Colbert; Kenneth L Rock
Journal:  Front Immunol       Date:  2021-03-09       Impact factor: 7.561

5.  Separate developmental programs for HLA-A and -B cell surface expression during differentiation from embryonic stem cells to lymphocytes, adipocytes and osteoblasts.

Authors:  Hardee J Sabir; Jan O Nehlin; Diyako Qanie; Linda Harkness; Tatyana A Prokhorova; Blagoy Blagoev; Moustapha Kassem; Adiba Isa; Torben Barington
Journal:  PLoS One       Date:  2013-01-18       Impact factor: 3.240

Review 6.  Targeted therapy in renal cell carcinoma: moving from molecular agents to specific immunotherapy.

Authors:  Jens Bedke; Cécile Gouttefangeas; Harpreet Singh-Jasuja; Stefan Stevanović; Carl-Ludwig Behnes; Arnulf Stenzl
Journal:  World J Urol       Date:  2013-02-12       Impact factor: 4.226

7.  Diagnostic and prognostic role of preoperative circulating CA 15-3, CA 125, and beta-2 microglobulin in renal cell carcinoma.

Authors:  Giuseppe Lucarelli; Pasquale Ditonno; Carlo Bettocchi; Antonio Vavallo; Monica Rutigliano; Vanessa Galleggiante; Angela Maria Vittoria Larocca; Giuseppe Castellano; Loreto Gesualdo; Giuseppe Grandaliano; Francesco Paolo Selvaggi; Michele Battaglia
Journal:  Dis Markers       Date:  2014-02-17       Impact factor: 3.434

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.